Navigation Links
Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
Date:9/7/2010

Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor... -- POINT RICHMOND, Calif., Sept. 7 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Banking & Financial Services, Health Care & Hospitals, Pharmaceuticals, Trade Show News Click to view news release full screen  

Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010

 

POINT RICHMOND, Calif., Sept. 7 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc.  (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to participate in these upcoming investor conferences:Rodman and Renshaw Annual Global Investment ConferenceNew York, NYSeptember 14, 2010 at 5:20 p.m. EDTA live audio webcast and replay of this presentation may be accessed at http://www.wsw.com/webcast/rrshq18/tspt and on the Transcept Investor webpage at www.transcept.com.Stifel Nicolaus Healthcare ConferenceBoston, MASeptember 16, 2010 at 9:10 a.m. EDTA live audio webcast and replay of this presentation may be accessed at http://www.veracast.com/webcasts/stifel/healthcare2010/65203465.cfm and on the Transcept Investor webpage at www.transcept.com.About TransceptTranscept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States.  Transcept is also developing TO-2061, an ultra low dose ondansetron augmentation therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to treatment with SSRIs.  Transcept plans to begin a Phase 2 study of TO-2061 in 2011.  For further information, please visit the Transcept website at: www.transcept.com.

Contact:Transcept Pharmaceuticals, Inc.Greg MannDirector, Corporate Communications(510) 215-3567gmann@transcept.com
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
2. Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter
3. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
4. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
5. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
6. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
7. Transcept Pharmaceuticals to Report First Quarter 2009 Results
8. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
9. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
10. Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Australie, le 24 février 2017 ITL Limited, ... santé diversifiée innovante, est ravie d,annoncer les excellents résultats ... la période précédente correspondante. Une présentation complète « Résultats et ... être consultée ici . Faits ... de 2,12 millions $ (Déc. 2015 : 1,04 million $ ; en hausse de ...
(Date:2/24/2017)... 2017 Medivir AB (Nasdaq Stockholm: ... new Board of Directors that will be submitted to ... comprises representatives of the company,s three largest shareholders at ... have accepted a seat on the Nomination Committee, and ... 2016-2017 Nomination Committee was as follows:  ...
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017  Genesis ... HME Company. The announcement was made by Bill ... David Hartley and Nathan Feltman , ... of Genesis Healthcare Services, LLC. This ... nation,s largest provider of technology enabled durable medical equipment ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now have ... Users have total control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, ... Pro X. , With ProGlass Prism users are given the tools and effects ...
(Date:2/24/2017)... ... , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently ... as the Chairman of the Management Committee when IFN was originally formed in 2002 ... of investor/owners and development of the business plan. He became the first paid ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... again hosted their Military Wedding Giveaway, with the winning couple announced on Feb. ... with services generously donated from local vendors: A Matter of Taste, Ryan Rousseau ...
(Date:2/23/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Beach to host its Swirl: Miami Wine Tasting Event on March 28, 2017. ...
(Date:2/23/2017)... ... 23, 2017 , ... Hamlin Dental Group and Dr. Hamid Reza, dentist ... Throughout the month of February, patients who visit Hamlin Dental Group will receive a ... for two at the Cheesecake Factory. , Tickets are available for routine dental ...
Breaking Medicine News(10 mins):